期刊
CURRENT PSYCHIATRY REVIEWS
卷 8, 期 2, 页码 140-150出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1573400511208020140
关键词
Cilostazol; Cognition; Glutamate; Glycine transporter inhibitor; Minocycline; Nicotinic receptor; Schizophrenia; Serotonin
类别
资金
- Comprehensive Research on Disability, Health and Welfare
- Health and Labour Sciences Research Grants, Japan
Cognitive impairment in patients with schizophrenia occurs in the prodromal phase and usually persists, even when psychotic symptoms have been successfully treated. There is a direct relationship between the level of cognitive impairment and functional outcome in schizophrenia, making these symptoms a new, potential therapeutic target. Although atypical antipsychotic drugs improve several domains of cognitive function, even when psychotic symptoms have been successfully treated, many patients, do not recover their cognitive impairment, resulting in a failure to reintegrate into society. Therefore, the development of new therapeutic drugs for cognitive impairment remains an imperative. In this review article, we discuss the merits of potential therapeutic drugs such as glycine transporter (GlyT-1) inhibitors, 5-HT1A receptor agonists, alpha 7 nicotinic acetylcholine receptor agonists, sigma-1 receptor agonists, minocycline and cilostazol.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据